Diagnosis and treatment of a patient with Kimura's disease associated with nephrotic syndrome and lymphadenopathy of the epitrochlear nodes.

Existing Reviews

Please note, new claims can take a short while to show up.

No claims yet.

Annotation Summary

Term Occurence Count Dictionary
focal segmental glomerulosclerosis 3 nephrologydiseases
glomerulonephritis 1 nephrologydiseases
methylprednisolone 13 nephrologydiseasesdrugs
nephrotic syndrome 13 nephrologydiseases
prednisolone 14 nephrologydiseasesdrugs

Graph of close proximity drug and disease terms (within 200 characters).

Note: If this graph is empty, then there are no terms that meet the proximity constraint.

Review

Having read the paper, please pick a pair of statements from the paper to indicate that a drug and disease are related.

Select Drug Character Offset Drug Term Instance
methylprednisolone 1959 effacement. His final diagnosis was Kimura's disease associated with nephrotic syndrome. He received methylprednisolone therapy as well as symptomatic treatment, and was discharged with key indicators in normal range on
methylprednisolone 2133 discharged with key indicators in normal range on September 17th 2013. During the year following, he had methylprednisolone at a maintenance dose of 8 mg/day, and no relapses occurred up to now.ConclusionMethylprednisolone therapy
methylprednisolone 2346 now.ConclusionMethylprednisolone therapy is effective in KD associated with nephrotic syndrome, and long-term administration of methylprednisolone at maintenance dose may be a way to prevent relapses of KD.BackgroundKimura’s disease (KD) is a rare,
methylprednisolone 7429 patient was KD associated with nephrotic syndrome (FSGS, cellular variant). He was given intravenous methylprednisolone (80 mg/day) for 3 days beginning on August 29th, 2013, followed by oral methylprednisolone (36 mg/d,
methylprednisolone 7520 intravenous methylprednisolone (80 mg/day) for 3 days beginning on August 29th, 2013, followed by oral methylprednisolone (36 mg/d, once a day). Meanwhile, he received famotidine (20 mg, twice a day), rocaltrol (0.25 μg,
methylprednisolone 8284 right arm. Therefore, the patient was discharged on September 17th 2013. After a 2-month period of methylprednisolone at a dose of 36 mg/day, the prescribed methylprednisolone dose was tapered by 4 mg every 2 weeks until
methylprednisolone 8342 September 17th 2013. After a 2-month period of methylprednisolone at a dose of 36 mg/day, the prescribed methylprednisolone dose was tapered by 4 mg every 2 weeks until a maintenance dose of 8 mg/day was reached. During the
methylprednisolone 9246 KD with renal involvement. In the present case, we observed a good response to 3 days of intravenous methylprednisolone (80 mg/day) with subsequent oral methylprednisolone (36 mg/day), and therefore proceeded to taper the
methylprednisolone 9298 observed a good response to 3 days of intravenous methylprednisolone (80 mg/day) with subsequent oral methylprednisolone (36 mg/day), and therefore proceeded to taper the methylprednisolone dosage to a long-term maintenance
methylprednisolone 9367 (80 mg/day) with subsequent oral methylprednisolone (36 mg/day), and therefore proceeded to taper the methylprednisolone dosage to a long-term maintenance dose (8 mg/day). At the time of writing this report, this regimen
methylprednisolone 10775 describe a successful treatment of Kimura's disease associated with nephrotic syndrome in a patient with methylprednisolone , and prevention of Kimura's disease relapses with long-term administration of methylprednisolone at
methylprednisolone 10872 with methylprednisolone, and prevention of Kimura's disease relapses with long-term administration of methylprednisolone at maintenance dose. Although we cannot conclude long-term administration of methylprednisolone is useful
methylprednisolone 10968 of methylprednisolone at maintenance dose. Although we cannot conclude long-term administration of methylprednisolone is useful as an effective strategy to prevent relapses yet, our report suggests that further studies
prednisolone 1965 effacement. His final diagnosis was Kimura's disease associated with nephrotic syndrome. He received methyl prednisolone therapy as well as symptomatic treatment, and was discharged with key indicators in normal range on
prednisolone 2139 with key indicators in normal range on September 17th 2013. During the year following, he had methyl prednisolone at a maintenance dose of 8 mg/day, and no relapses occurred up to now.ConclusionMethylprednisolone therapy
prednisolone 2238 methylprednisolone at a maintenance dose of 8 mg/day, and no relapses occurred up to now.ConclusionMethyl prednisolone therapy is effective in KD associated with nephrotic syndrome, and long-term administration of methylprednisolone
prednisolone 2352 therapy is effective in KD associated with nephrotic syndrome, and long-term administration of methyl prednisolone at maintenance dose may be a way to prevent relapses of KD.BackgroundKimura’s disease (KD) is a rare,
prednisolone 7435 was KD associated with nephrotic syndrome (FSGS, cellular variant). He was given intravenous methyl prednisolone (80 mg/day) for 3 days beginning on August 29th, 2013, followed by oral methylprednisolone (36 mg/d,
prednisolone 7526 intravenous methylprednisolone (80 mg/day) for 3 days beginning on August 29th, 2013, followed by oral methyl prednisolone (36 mg/d, once a day). Meanwhile, he received famotidine (20 mg, twice a day), rocaltrol (0.25 μg,
prednisolone 8290 arm. Therefore, the patient was discharged on September 17th 2013. After a 2-month period of methyl prednisolone at a dose of 36 mg/day, the prescribed methylprednisolone dose was tapered by 4 mg every 2 weeks until
prednisolone 8348 17th 2013. After a 2-month period of methylprednisolone at a dose of 36 mg/day, the prescribed methyl prednisolone dose was tapered by 4 mg every 2 weeks until a maintenance dose of 8 mg/day was reached. During the
prednisolone 9252 renal involvement. In the present case, we observed a good response to 3 days of intravenous methyl prednisolone (80 mg/day) with subsequent oral methylprednisolone (36 mg/day), and therefore proceeded to taper the
prednisolone 9304 a good response to 3 days of intravenous methylprednisolone (80 mg/day) with subsequent oral methyl prednisolone (36 mg/day), and therefore proceeded to taper the methylprednisolone dosage to a long-term maintenance
prednisolone 9373 mg/day) with subsequent oral methylprednisolone (36 mg/day), and therefore proceeded to taper the methyl prednisolone dosage to a long-term maintenance dose (8 mg/day). At the time of writing this report, this regimen
prednisolone 10781 successful treatment of Kimura's disease associated with nephrotic syndrome in a patient with methyl prednisolone , and prevention of Kimura's disease relapses with long-term administration of methylprednisolone at
prednisolone 10878 methylprednisolone, and prevention of Kimura's disease relapses with long-term administration of methyl prednisolone at maintenance dose. Although we cannot conclude long-term administration of methylprednisolone is useful
prednisolone 10974 methylprednisolone at maintenance dose. Although we cannot conclude long-term administration of methyl prednisolone is useful as an effective strategy to prevent relapses yet, our report suggests that further studies
Select Disease Character Offset Disease Term Instance
focal segmental glomerulosclerosis 1593 epitrochlear nodes revealed eosinophilic hyperplastic lymphogranulomatous tissue. A renal biopsy indicated focal segmental glomerulosclerosis (FSGS) (cellular variant) with no infiltration of eosinophil in renal interstitium. The results of immune-staining
focal segmental glomerulosclerosis 3587 endothelium.Here, we present the case of a patient with KD associated with nephrotic syndrome characterized by focal segmental glomerulosclerosis (FSGS). We also provide an analysis of the diagnostic strategy for recognizing KD associated with nephrotic
focal segmental glomerulosclerosis 6053 epitrochlear nodes revealed eosinophilic hyperplastic lymphogranulomatous tissue. A renal biopsy indicated focal segmental glomerulosclerosis (FSGS) (cellular variant) with no infiltration of eosinophil in renal interstitium (Figure 1B). The
glomerulonephritis 9743 associated with nephrotic syndrome, including minimal change disease [[6]], mesangio-proliferative glomerulonephritis [[7]], membranous nephropathy [[8]], FSGS, IgA nephropathy, IgM nephropathy, and IgE nephropathy. Inexplicably,
nephrotic syndrome 98 Title: BMC NephrologyDiagnosis and treatment of a patient with Kimura’s disease associated with nephrotic syndrome and lymphadenopathy of the epitrochlear nodesSheng-lang ZhuPeng-fei WeiJie-hui ChenZhen-fu ZhaoQian-na
nephrotic syndrome 831 KD cases. We report the case of a 23-year-old Chinese man who was found to have KD associated with nephrotic syndrome .Case presentationA 23-year-old Chinese man presented with edema in both legs and a mass in ulnar side
nephrotic syndrome 1927 microscopic analysis showed podocyte effacement. His final diagnosis was Kimura's disease associated with nephrotic syndrome . He received methylprednisolone therapy as well as symptomatic treatment, and was discharged with key
nephrotic syndrome 2294 relapses occurred up to now.ConclusionMethylprednisolone therapy is effective in KD associated with nephrotic syndrome , and long-term administration of methylprednisolone at maintenance dose may be a way to prevent relapses
nephrotic syndrome 3142 involvement [[3]]. Indeed, when there is renal involvement, the disease may present initially as a nephrotic syndrome . KD is diagnosed after the exclusion of malignancies (e.g., T-cell lymphoma and Hodgkin’s disease
nephrotic syndrome 3551 lymphoid follicles and vascular endothelium.Here, we present the case of a patient with KD associated with nephrotic syndrome characterized by focal segmental glomerulosclerosis (FSGS). We also provide an analysis of the diagnostic
nephrotic syndrome 3720 glomerulosclerosis (FSGS). We also provide an analysis of the diagnostic strategy for recognizing KD associated with nephrotic syndrome , as well as treatments and methods to prevent the relapse of this condition.Case presentationA 23-year-old
nephrotic syndrome 7359 eosinophil is found in renal interstitium.The final diagnosis for this patient was KD associated with nephrotic syndrome (FSGS, cellular variant). He was given intravenous methylprednisolone (80 mg/day) for 3 days beginning
nephrotic syndrome 8676 occurred.DiscussionIn this report, we described the case of a 23-year-old Chinese man who developed KD with nephrotic syndrome 3 years after the appearance of a tumor-like subcutaneous mass. The subcutaneous mass was located in
nephrotic syndrome 9660 renal involvement in KD is not yet known. Various renal pathologies may present in KD associated with nephrotic syndrome , including minimal change disease [[6]], mesangio-proliferative glomerulonephritis [[7]], membranous
nephrotic syndrome 9916 nephropathy, IgM nephropathy, and IgE nephropathy. Inexplicably, we observed the complete remission of the nephrotic syndrome in this patient within 6 days of commencing corticosteroid treatment. This is remarkably rapid given
nephrotic syndrome 10088 corticosteroid treatment. This is remarkably rapid given that the average remission time for FSGS in primary nephrotic syndrome patients treated with corticosteroids is 4 months.Rare diseases are likely to be misdiagnosed as doctors
nephrotic syndrome 10738 thinking abilities.ConclusionsWe describe a successful treatment of Kimura's disease associated with nephrotic syndrome in a patient with methylprednisolone, and prevention of Kimura's disease relapses with long-term administration

You must be authorized to submit a review.